INAB News & Events

IN8bio announced the promotion of Kate Rochlin, Ph.D., to President and COO, effective immediately. Dr. Rochlin has served as IN8bio's COO since December 2021, following her tenure as Vice President and Associate Vice President of Operations and Innovation beginning in August 2020. In her expanded role, she will continue to oversee company operations as IN8bio advances its clinical and preclinical pipeline and prepares for its next phase of growth.

IN8bio files to sell 14.38M shares of common stock for holders

IN8bio reported updated clinical data from its INB-200 Phase 1 and INB-400 Phase 2 trials in newly diagnosed glioblastoma. The prior results were presented at the 2025 Society for Neuro-Oncology Annual Meeting. The data continue to demonstrate meaningful and durable improvements in progression-free survival when compared with both historical standard-of-care Stupp protocol data and concurrently enrolled SOC treated patients. Patients in both the Phase 1 and 2 who received repeated doses of the Company's investigational therapy, DeltEx Drug-Resistant Immunotherapy gamma-delta T cells, experienced substantial improvements in both median progression-free and median overall survival across multiple clinical centers. This data is put into greater context compared to contemporaneously enrolled patients treated only with SOC at the same clinical trial sites, forming a concurrently treated control cohort: Median progression-free survival: DeltEx DRI 13.0 months vs. 6.6 months with SOC. Median overall survival: DeltEx DRI, not yet reached, currently 17.2+ months and rising, compared with 13.2 months for SOC. Durability: DeltEx DRI, eight of fourteen patients remained progression-free longer than their expected overall survival based on age and MGMT status, compared with just a single patient in the control group. Long-term benefit: Several DeltEx DRI treated patients remain progression-free beyond two years without experiencing any significant DRI related SAEs or DLTs. For the first time, IN8bio presented data from a control group of patients that were contemporaneously enrolled and treated only with the SOC protocols at the same clinical centers with the same treating physicians as the DeltEx DRI cohorts. The SOC control patients performed in-line with expectations based on historical GBM mPFS of 6.9 months, despite a greater number of patients receiving gross total resections. This demonstrates both the aggressive nature of GBM, even with SOC treatment, and the significant need for new treatment options. The funds received from IN8bio's recent financing announced late in 2025 will support further discussions with the FDA on potential clinical pathways, including any potential for accelerated approval. Across both Phase 1, INB-200, and Phase 2, INB-400, trials at multiple centers, DeltEx DRI gammadelta T cells continued to demonstrate a well-tolerated safety profile, with: No DLTs; No cytokine release syndrome; No immune effector cell-associated neurotoxicity; No unexpected infections or SAEs.

IN8bio entered into a definitive securities purchase agreement with certain institutional and accredited investors for up to approximately $40.2M in gross proceeds through a private placement, priced at-the-market under Nasdaq rules. The net proceeds from the initial tranche of the financing are expected to fund the Company's current operating plans into the first half of 2027. The private placement includes new and existing investors including Coastlands Capital, Stonepine Capital Management and 683 Capital Partners along with directors and officers of the Company. H.C. Wainwright & Co. is acting as the exclusive placement agent for the private placement. Under the terms of the SPA, the private placement includes an initial closing of approximately $20.1M in gross proceeds. At the initial closing, the Company will sell 5,127,029 shares of common stock at a purchase price of $1.38 per share and, in lieu of common stock, pre-funded warrants to purchase up to 9,452,677 shares of common stock, at a purchase price $1.3799 for each pre-funded warrant. The pre-funded warrants will have an exercise price of $0.0001 per share and will be immediately exercisable. The Company will be eligible to receive up to an additional approximately $20.1M in gross proceeds in exchange for up to 14,579,706 shares of common stock, subject to achieving certain milestone-driven conditions related to preclinical data for the Company's CD-19 targeting INB-619 product candidate and share price. The initial closing of the private placement is expected to occur on or about December 22, 2025, subject to satisfaction of customary closing conditions.